In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avanir Relying On PBA Drug Nuedexta For Success

This article was originally published in The Pink Sheet Daily

Executive Summary

Approved last year for pseudobulbar affect and gradually gaining sales and formulary adoption, Nuedexta will be studied in additional CNS indications.
Advertisement

Related Content

Hill Democrats Continue Inquiries Into High Prices For New Versions Of Old Drugs; Avanir's Nuedexta And URL Pharma's Colcrys Targeted
Positive Phase III Data For Tasocitinib Give Pfizer A Badly Needed Pipeline Lift
Positive Phase III Data For Tasocitinib Give Pfizer A Badly Needed Pipeline Lift

Topics

Advertisement
UsernamePublicRestriction

Register

PS072499

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel